Skip to main content
Ralph Payne

Featured Patient Story

Ralph Payne

Written by Debra Payne, Wife and Caregiver

read more

Latest News Story Headlines

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk o

read full article
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.
read full article
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

read full article

Calendar & Upcoming Events

How to Handle Setbacks on your amyloidosis journey

view all event details

Dans TOP 5 Tips for Thriving with Amyloidosis

view all event details

Amyloidosis Videos

Our Latest Webinar

Updates in AL amyloidosis: Fast Forward in 2024!

Heather Landau, MD - Memorial Sloan Kettering Cancer Center - New York, NY

Sign Up for the Latest Updates

Get news from Amyloidosis Foundation
in your inbox

By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.